FDA approves ozempic for type 2 diabetes

FDA approves ozempic for type 2 diabetes

(HealthDay)—A new once-weekly diabetes medication that lowers blood glucose and also helps patients lose weight has been approved by the U.S. Food and Drug Administration.

The once-a-week injection drug Ozempic (semaglutide) is approved for patients with type 2 diabetes. It stimulates the body's and reduces appetite, the Associated Press reported.

The drug is from Danish company Novo Nordisk. A company-funded study of 1,200 type 2 found those who took Ozempic had average reductions in long-term levels at least 2.5 times greater than those who took daily sitagliptin.

Patients who took Ozempic also lost two to three times as much weight as those in the comparison group, the AP reported.


Explore further

Ozempic approved for type 2 diabetes

More information: More Information

Copyright © 2017 HealthDay. All rights reserved.

Citation: FDA approves ozempic for type 2 diabetes (2017, December 6) retrieved 24 August 2019 from https://medicalxpress.com/news/2017-12-fda-ozempic-diabetes.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
0 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more